| Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS (NCT04893915) | Washington University School of Medicine | 2022-06-30 |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (NCT04797767) | University of Washington | 2022-02-04 |
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 (NCT04874194) | M.D. Anderson Cancer Center | 2021-12-17 |
| Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia (NCT04898894) | St. Jude Children's Research Hospital | 2021-11-15 |
| Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS (NCT04749355) | BioSight Ltd. | 2021-11-14 |
| Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (NCT04975919) | M.D. Anderson Cancer Center | 2021-09-29 |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT05010122) | M.D. Anderson Cancer Center | 2021-07-08 |
| FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies (NCT04891757) | Foghorn Therapeutics Inc. | 2021-06-14 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation (NCT03602898) | Fred Hutchinson Cancer Center | 2021-06-01 |
| Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (NCT04774393) | M.D. Anderson Cancer Center | 2021-05-24 |
| Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia (NCT04915612) | M.D. Anderson Cancer Center | 2021-05-21 |
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia (NCT04526795) | M.D. Anderson Cancer Center | 2021-04-09 |
| Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (NCT04835519) | Beijing Boren Hospital | 2021-04-08 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (NCT04752163) | M.D. Anderson Cancer Center | 2021-03-25 |
| Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia (NCT04746235) | M.D. Anderson Cancer Center | 2021-02-22 |
| Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML. (NCT04904237) | Shanghai Jiao Tong University School of Medicine | 2021-01-01 |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT04493164) | M.D. Anderson Cancer Center | 2020-12-30 |
| Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia (NCT04250051) | Northwestern University | 2020-12-21 |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (NCT04375631) | Fred Hutchinson Cancer Center | 2020-12-03 |
| Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia (NCT04207190) | Roswell Park Cancer Institute | 2020-10-23 |
| Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML (NCT04493099) | M.D. Anderson Cancer Center | 2020-10-01 |
| Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation (NCT03953898) | National Cancer Institute (NCI) | 2020-08-04 |
| Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia (NCT04435691) | M.D. Anderson Cancer Center | 2020-07-28 |
| Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome (NCT04487106) | M.D. Anderson Cancer Center | 2020-07-21 |
| Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML (NCT04220684) | Sumithira Vasu | 2020-06-11 |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (NCT04128748) | M.D. Anderson Cancer Center | 2020-05-27 |
| Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia (NCT04188405) | M.D. Anderson Cancer Center | 2020-05-17 |
| Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms (NCT04196010) | University of Washington | 2020-05-08 |
| Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia (NCT04562792) | Children's Mercy Hospital Kansas City | 2020-05-08 |
| Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia (NCT03983824) | National Cancer Institute (NCI) | 2020-05-05 |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory (NCT03969446) | City of Hope Medical Center | 2020-05-04 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement (NCT03701295) | National Cancer Institute (NCI) | 2020-03-06 |
| Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia (NCT04158739) | Children's Oncology Group | 2020-01-22 |
| Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm (NCT04140487) | M.D. Anderson Cancer Center | 2019-12-17 |
| Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation (NCT03881735) | Roswell Park Cancer Institute | 2019-12-02 |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT04047641) | M.D. Anderson Cancer Center | 2019-10-22 |
| Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias (NCT04000698) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2019-10-15 |
| ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT04013880) | Vanderbilt-Ingram Cancer Center | 2019-08-27 |
| Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT03874052) | Jennifer Saultz | 2019-08-16 |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03670966) | Fred Hutchinson Cancer Center | 2019-07-10 |
| Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT03772925) | National Cancer Institute (NCI) | 2019-06-20 |
| Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT03745352) | National Cancer Institute (NCI) | 2019-05-20 |
| Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT03813147) | National Cancer Institute (NCI) | 2019-05-17 |
| TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia (NCT03752138) | M.D. Anderson Cancer Center | 2019-03-31 |
| Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia (NCT03634228) | M.D. Anderson Cancer Center | 2018-12-17 |
| Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML (NCT05456048) | Nanfang Hospital, Southern Medical University | 2018-12-03 |
| Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (NCT03672539) | M.D. Anderson Cancer Center | 2018-11-07 |
| Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome (NCT03661307) | M.D. Anderson Cancer Center | 2018-10-31 |
| Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia (NCT03629171) | M.D. Anderson Cancer Center | 2018-10-29 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (NCT03630991) | M.D. Anderson Cancer Center | 2018-10-11 |
| Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT03600155) | M.D. Anderson Cancer Center | 2018-10-11 |
| JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia (NCT03557970) | OHSU Knight Cancer Institute | 2018-10-05 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (NCT03289910) | National Cancer Institute (NCI) | 2018-09-24 |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation (NCT03683433) | M.D. Anderson Cancer Center | 2018-09-18 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia (NCT03519984) | University of Southern California | 2018-05-09 |
| Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies (NCT03471260) | M.D. Anderson Cancer Center | 2018-03-19 |
| Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (NCT03041688) | National Cancer Institute (NCI) | 2018-02-08 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (NCT03404193) | M.D. Anderson Cancer Center | 2018-01-18 |
| Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia (NCT03035422) | Association for Training, Education, and Research in Hematology, Immunology, and Transplantation | 2018-01-15 |
| OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia (NCT03390296) | M.D. Anderson Cancer Center | 2017-12-27 |
| Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT03067571) | M.D. Anderson Cancer Center | 2017-10-27 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (NCT03128034) | Fred Hutchinson Cancer Center | 2017-10-24 |
| Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia (NCT03291353) | Michael Boyiadzis | 2017-10-17 |
| Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia (NCT03214562) | M.D. Anderson Cancer Center | 2017-09-26 |
| Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT02890329) | National Cancer Institute (NCI) | 2017-09-05 |
| Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia (NCT03009240) | City of Hope Medical Center | 2017-08-21 |
| Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant (NCT03247088) | M.D. Anderson Cancer Center | 2017-07-30 |
| Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia (NCT03132454) | M.D. Anderson Cancer Center | 2017-07-25 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (NCT03017820) | Mayo Clinic | 2017-04-04 |
| STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy (NCT03063944) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2017-03-17 |
| Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia (NCT02953561) | M.D. Anderson Cancer Center | 2017-02-20 |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS (NCT02921061) | Fred Hutchinson Cancer Center | 2016-11-17 |
| Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms (NCT02756572) | University of Washington | 2016-09-22 |
| Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (NCT02159495) | City of Hope Medical Center | 2015-12-15 |
| ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome (NCT02392572) | M.D. Anderson Cancer Center | 2015-11-03 |
| High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NCT02551718) | University of Washington | 2015-09-11 |
| 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02509546) | City of Hope Medical Center | 2015-09-02 |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (NCT02381548) | National Cancer Institute (NCI) | 2015-08-18 |
| Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML (NCT02109627) | C. Babis Andreadis | 2015-05-01 |
| Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia (NCT02399917) | M.D. Anderson Cancer Center | 2015-04-20 |
| Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (NCT02397720) | M.D. Anderson Cancer Center | 2015-04-07 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD (NCT02220985) | Fred Hutchinson Cancer Center | 2015-03-23 |
| Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia (NCT02257138) | M.D. Anderson Cancer Center | 2015-02-12 |
| Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (NCT02070458) | Case Comprehensive Cancer Center | 2014-10-08 |
| Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01787474) | M.D. Anderson Cancer Center | 2014-05-19 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia (NCT02115295) | M.D. Anderson Cancer Center | 2014-05-19 |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT01892371) | M.D. Anderson Cancer Center | 2013-11-12 |
| Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01961765) | Massachusetts General Hospital | 2013-11-01 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia (NCT01620216) | OHSU Knight Cancer Institute | 2012-05-11 |
| Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT01130506) | National Cancer Institute (NCI) | 2010-05-17 |
| GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies (NCT00426205) | Dana-Farber Cancer Institute | 2004-06-01 |